Barclays unveils £14bn lending fund to help businesses through Brexit uncertainty

first_img Barclays unveils £14bn lending fund to help businesses through Brexit uncertainty More From Our Partners Florida woman allegedly crashes children’s birthday party, rapes teennypost.comPolice Capture Elusive Tiger Poacher After 20 Years of Pursuing the Huntergoodnewsnetwork.orgA ProPublica investigation has caused outrage in the U.S. this weekvaluewalk.comMatt Gaetz swindled by ‘malicious actors’ in $155K boat sale boondogglenypost.comAstounding Fossil Discovery in California After Man Looks Closelygoodnewsnetwork.orgInside Ashton Kutcher and Mila Kunis’ not-so-average farmhouse estatenypost.comNative American Tribe Gets Back Sacred Island Taken 160 Years Agogoodnewsnetwork.orgRussell Wilson, AOC among many voicing support for Naomi Osakacbsnews.comBrave 7-Year-old Boy Swims an Hour to Rescue His Dad and Little Read more: Businesses not prepared for increased post-Brexit recruitment costs“It is the entrepreneurs, farmers, manufacturers, housebuilders, new tech firms and countless other businesses that will help the country deal with – and capitalise on – this period of change.”“Barclays is here to help SMEs to do exactly that,” Staley added. whatsapp Tags: Trading Archive Read more: Barclays: No-deal Brexit would ‘significantly’ hurt the EUThe Bank of England’s governor Mark Carney has warned last month that half of UK firms are not ready for a no-deal Brexit, according to recent surveys.UK Finance then launched a no-deal Brexit survival guide for SMEs, which included speaking to banks about extra finance as soon as possible and considering the impact of potential changes to trading arrangements.Barclays said the £14.7bn was to help businesses, at various stages of growth and development, deal with and capitalise on Brexit uncertainty.Chief executive Jes Staley said: “Barclays stands ready to help local businesses in towns, cities and rural communities up and down the country during this period of uncertainty. center_img Wednesday 27 March 2019 12:01 am Share whatsapp Callum Keown Barclays has unveiled a £14bn lending fund to help small and medium-sized businesses through the uncertainty of Brexit.The bank, which has held more than 100 “Brexit clinics” for businesses in recent weeks, said the fund would provide loans, commercial mortgages and cash flow funding for investments.last_img read more

How and when will the UK coronavirus lockdown end?

first_imgFriday 24 April 2020 5:09 pm Chancellor Rishi Sunak, Cabinet Office minister Michael Gove and trade secretary Liz Truss have all expressed concern about the impact of an extended lockdown on the economy. Prime Minister Boris Johnson has been out of action as he recovers from coronavirus at Chequers, but now plans on returning to work as soon as Monday. whatsapp This week health secretary Matt Hancock confirmed the coronavirus outbreak has passed its peak, sparking speculation about an exit strategy from the UK lockdown. The economic impact of quarantine (Getty Images) Also Read: How and when will the UK coronavirus lockdown end? Show Comments ▼ (Getty Images) Ministers have outlined five key tests that must be met before restrictions can be lifted: He warned social distancing would have to be in place for at least the rest of 2020. Ministers have also said an easing of the UK coronavirus lockdown would depend on the launch and widespread uptake of an NHS contact tracing app. This would notify people if they have come close to someone who has tested positive for Covid-19. James Warrington Testing is now available to essential workers, but the government is still less than a quarter of a way to its target of 100,000 tests per day by the end of April. According to reports, ministers are drawing up a three-stage approach to easing restrictions between May and July. Michael Gove has said he welcomed a “public debate” on the sensitive issue of when and how to lift the lockdown. Moreover, eliminating the risk of a second peak — one of the key factors for lifting restrictions — will prove difficult. More From Our Partners Native American Tribe Gets Back Sacred Island Taken 160 Years Agogoodnewsnetwork.orgWhy people are finding dryer sheets in their mailboxesnypost.comPolice Capture Elusive Tiger Poacher After 20 Years of Pursuing the Huntergoodnewsnetwork.orgA ProPublica investigation has caused outrage in the U.S. this weekvaluewalk.comBrave 7-Year-old Boy Swims an Hour to Rescue His Dad and Little Sistergoodnewsnetwork.orgRussell Wilson, AOC among many voicing support for Naomi Osakacbsnews.comAstounding Fossil Discovery in California After Man Looks Closelygoodnewsnetwork.orgFlorida woman allegedly crashes children’s birthday party, rapes teennypost.comBiden received funds from top Russia lobbyist before Nord Stream 2 giveawaynypost.com980-foot skyscraper sways in China, prompting panic and‘The Love Boat’ captain Gavin MacLeod dies at 90nypost.comFeds seized 18 devices from Rudy Giuliani and his employees in April raidnypost.comMatt Gaetz swindled by ‘malicious actors’ in $155K boat sale boondogglenypost.comKiller drone ‘hunted down a human target’ without being told tonypost.comI blew off Adam Sandler 22 years ago — and it’s my biggest regretnypost.comInside Ashton Kutcher and Mila Kunis’ not-so-average farmhouse estatenypost.comUK teen died on school trip after teachers allegedly refused her‘Neighbor from hell’ faces new charges after scaring off home (Getty Images) Also Read: How and when will the UK coronavirus lockdown end? But any decision on when and how to lift the UK coronavirus lockdown will depend on whether the virus transmission rate — known as the R number — has reduced to a manageable level. Last week the government said the UK coronavirus lockdown would continue for at least another three weeks. But when — and how — will this state of quarantine end? Chief medical officer Chris Whitty has warned the only way to ensure a return to normal would be the widespread availability of a vaccine or drug. While health concerns are central to the UK’s approach, authorities must also take into account the economic impact of the pandemic. Backbench Tory MPs have also weighed in on the debate, warning that thousands of businesses were on the verge of collapse.center_img Pubs and restaurants could then be reopened later in the summer. And so-called shielding arrangements to protect elderly and vulnerable people could be kept in place for the longer term. Ultimately, though, the government will need to overcome divisions in the Cabinet and come to a collective decision. Striking this balance has proved controversial, and Boris Johnson’s Cabinet is understood to be divided over the subject. Making sure the NHS can copeA ‘sustained and consistent’ fall in the daily death rateA decline in the infection rateEnsuring supplies of personal protection equipment (PPE) and tests can meet demandNo risk of a second peak in the virus Listen to our daily City View podcast as we chart the economic fallout and business impact of the coronavirus pandemic. Who makes the final decision? Phased approach to end UK coronavirus lockdown Wales has outlined a “traffic light” system to gradually ease lockdown, beginning at the end of the current three-week period. The chances of having one of these in the next calendar year are “incredibly small”, Whitty said. However, officials have poured cold water on the idea that Britain could return to normal soon. So far, the NHS appears to have coped well with the crisis. Cancellations of routine appointment and procedures — as well as the new Nightingale field hospitals — have freed up thousands of beds. Others, including Hancock, want to wait until the R number is close to zero before easing restrictions, arguing that a second wave of infections would be more damaging. whatsapp (Getty Images) Also Read: How and when will the UK coronavirus lockdown end? The five tests The daily coronavirus death rate is also beginning to fall. First minister Nicola Sturgeon has warned the lifting of restrictions in Scotland would be “incremental” rather than a “flick-of-the-switch moment”. How and when will the UK coronavirus lockdown end? Share Under these plans, some shops and businesses could be allowed to reopen in early to mid-May. Restrictions on people leaving their homes would be gradually relaxed. While the UK government is yet to confirm an exit strategy, it seems likely that any lifting of coronavirus lockdown measures will happen gradually. (Getty Images) Also Read: How and when will the UK coronavirus lockdown end? Tags: Coronaviruslast_img read more

Skagway Assembly wrestles with vacation rentals, RV’s, parking

first_imgCommunity | Local Government | SoutheastSkagway Assembly wrestles with vacation rentals, RV’s, parkingApril 23, 2018 by Daysha Eaton, KHNS-Haines Share:Skagway Assembly Chambers. (Photo by Greta Mart)Finding housing in Skagway can be difficult especially this time of year.The Skagway Assembly introduced at its Thursday meeting an ordinance to regulate vacation rentals.“As you all know, we are having a housing crisis — both long-term and seasonal and we are working hard for solutions,” Skagway Mayor Monica Carlson said.Local lodge owner Kathy Hosford of Dyea said during citizen testimony she thought Airbnb was negatively affecting her business. She spoke out against passing the ordinance until changes are made and suggested more regulation for vacation rentals.“A state license that is required by law be obtained, a city license after that, a DEC inspection of water and sewer,” Hosford said.“A conditional-use permit by all means, so that neighbors could weigh in, and a fire marshal inspection, and off-street parking be verified,” she said. “Competition is very good, but for those of us that went through a different process so that we could have overnight accommodations; this is the toolbox that we had to work with.”The Assembly postponed the ordinance until when the Planning and Zoning Commission reviews it May 10. Then it should come back to the Assembly for introduction.The Assembly also took up a resolution aimed at regulating the number of people living in recreational vehicles in Skagway.Living in an RV is illegal unless you are permitted or living at an RV park in municipal code compliance.The municipality has two existing RV parks. Two others recently closed.The community plans to develop an additional RV park in three years.In order to transition residents from RV’s to other housing or RV parks, the Assembly plans to continue allowing existing RV’s outside parks to remain with a permit.After three years, the Assembly will begin enforcing its code and fine those living outside official parks a $100 per day.Under the new rules, permitted RV’s will be allowed on private property in all zones except the historic and waterfront districts, and on property used for congregant housing.The Assembly adopted the resolution A temporary plan is in place to transition those out of compliance with code into compliant living situations.In the meantime, RV’s must be licensed, connected to water and sewer utilities, and have a safety inspection in order to obtain a permit from the city, which costs $300 per year, among other things.Anyone without a permit will be fined under the existing code and required to pay $100 per day.The temporary plan sunsets May 1, 2021, when all RV’s must be compliant with code.The Assembly also took up a parking resolution aimed at eliminating congestion in the downtown area.Members amended the resolution to allow the municipality to issue parking permits for year-round residents who live in the downtown area and postponed it to allow for further committee review.A public committee meeting about the parking resolution is scheduled for 5 p.m. Monday, April 23, in Assembly Chambers.Skagway Assembly will meet at 7 p.m. May 3.Share this story:last_img read more

Pharmalot, Pharmalittle: Johnson & Johnson to publish drug price hikes

first_img Alex Hogan/STAT Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Pharmalot, Pharmalittle: Johnson & Johnson to publish drug price hikes About the Author Reprints Ed Silverman Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. First 30 days free. GET STARTED GET STARTED [email protected] @Pharmalot Pharmalot center_img Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. Tags drug pricingfinancepharmaceuticalsSTAT+ What is it? By Ed Silverman Jan. 10, 2017 Reprints Hello, everyone, and how are you today? We are just fine, thank you, despite daunting weather that altered travel plans. Nonetheless, we managed to arrive at the JP Morgan health care fest, albeit not as soon as we hoped, and plan to scurry about meeting interesting people. As we indicated previously, this will call for sporadic posting. Nonetheless, we have assembled the usual menu of tidbits. We will now search for a cup of stimulation. Have a grand day and do keep in touch …Johnson & Johnson is set to issue a report next month outlining how much it has raised US prices for its prescription drugs, the Wall Street Journal writes. The report will provide the average increase in list prices, as well as average prices after the discounts given by the health care giant. But J&J is not pledging to hold price hikes to single-digit increases, because the company maintains it already does so. STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Log In | Learn More What’s included?last_img read more

The two months in 1980 that shaped the future of biotech

first_img Related: Tags biotechnology By Henry T. Greely Oct. 17, 2020 Reprints Biotech’s behind-the-scenes baroness redefined how universities launch startups About the Author Reprints Event 2: A biotech IPOAround the same time Berg was learning he had won a Nobel Prize, the common stock of a 4-year-old biotech company named Genentech made its initial public offering on the New York Stock Exchange. Genentech’s business was based on recombinant DNA and its first products (still two years in the future at that point) were human proteins made by bacteria into which human genes had been slipped using recombinant DNA techniques. When the market opened, the stock traded for $35 per share. By the end of the day investors had blasted its price higher — all the way up to $88 per share — before closing at $71.The first biotech boom was on, leading many other fledgling biotech startups to go public in the next few months. Did Genentech’s impressive IPO owe any of its oomph to that morning’s announcement of Berg’s Nobel Prize for recombinant DNA? We can never know.Event 3: A new innovation lawExactly one week later, on October 21, President Jimmy Carter signed into law the Stevenson Wydler Technology Innovation Act. It responded to concerns that government-sponsored technologies were not being commercialized frequently enough. The act encouraged U.S. national laboratories, such as Fermilab, Brookhaven, Oak Ridge, Los Alamos, and the Stanford Linear Accelerator Center, among others, to spread information about government-owned technology, in part by requiring them to establish Offices of Research and Technology Applications that were to identify and promote technologies with strong commercial potential. The Carter administration supported this bill in part because it kept control over who would commercialize those new technologies in the hands of the federal government.This is the least important of the five events for biotechnology. The National Labs, though engaged in a surprising amount of biological research for organizations derived from nuclear weapons research, were not then hotbeds of bioscience and biotech innovation. Event 4: A game-changing patentTuesday, December 2, marked the fourth, quietest, but not the least important of this string of biotech events. The U.S. Patent and Trademark Office granted U.S. Patent No. 4,237,224, “Process for producing biologically functional molecular chimera,” to two inventors, Stanley N. Cohen of Stanford and Herbert W. Boyer of the University of California, San Francisco. The patent was assigned to Leland Stanford Junior University and the Regents of the University of California. As my colleague Jacob Sherkow and I wrote in 2015:“That patent, the result of research conducted in 1974 on a process of creating recombinant DNA, i.e., recombining genes, appeared to be the holy grail for geneticists. Rather than tedious mutational or crossbreeding studies, the Cohen-Boyer technology allowed genetics researchers to study — and create — genes in isolation. With increasing research into the function and characterization of restriction enzymes, recombinant DNA technology opened doors for researchers to both isolate and purify individual genes as well as create analogs of their own.”I haven’t been able to find any significant publicity about this patent around the time it was awarded, but for the next two decades the Cohen-Boyer patent formed the cornerstone of both the biotech industry and of much biological research. It broadly claimed the methods of recombinant DNA and earned its assignees about $400 million.Stanford administered the Cohen-Boyer patent and took 15% of the proceeds for its trouble. The remainder was split evenly by Stanford and the University of California system, which distributed them in different ways. Stanford’s practice was (and remains) to give one-third of the proceeds to the inventor, one-third to the inventor’s department, and one-third to the inventor’s school. This bonanza for Stanford Medical School’s genetics department, of which Cohen was a member — about $70 million — did not endear it to Berg’s and Kornberg’s biochemistry department, which had done, in Berg’s lab and elsewhere, much of the research on recombinant DNA. On the other hand, the genetics department had been none too pleased by who had (and had not) received the Nobel Prize.It isn’t clear to me if anyone fully realized at the time the patent was granted how important — or lucrative — it would be. Eventually, though, the Cohen-Boyer patent helped change how universities approached commercializing research. Its large returns prompted first scores, and then hundreds, of colleges and universities to open technology licensing offices. Today about 200 such offices exist, although only about a dozen are profitable in any given year (and these are largely the same ones every year, including Stanford’s and the University of California’s). [email protected] Event 5: Bayh-Dole becomes lawThe fifth and final event took place on Friday, December 12, when then-lame duck President Jimmy Carter signed the Patent and Trademark Law Amendments Act, better known as the Bayh-Dole Act. This law gave universities and other nonprofit research institutions a clear and easy way to own intellectual property they created, in whole or in part, with federal research funding. It is often credited with having kickstarted the biotech industry. Along with the success of the Cohen-Boyer patent, it certainly encouraged universities to view some parts of biology as potential profit centers.But it almost didn’t come to fruition. In the course of just under two months that started 40 years ago this week, five events occurred that shaped the biotechnology industry and bioscience research. Looking back on these seminal events is a reminder of the odd ways in which change happens.Event 1: A Nobel PrizeEarly in the morning of Tuesday, October 14, 1980, the phone rang at Paul Berg’s house in Stanford, Cal. The jangling phone worried Berg and his wife because Berg’s father was old and ill, and they feared the worst. Instead, Berg heard the voice of his Stanford colleague, Arthur Kornberg, telling him that Paul had been awarded the Nobel Prize for Chemistry. The Swedish Royal Academy had been unable to find Berg’s unlisted phone number, but one of Kornberg’s sons had heard the news very early in the morning on the radio and called his father, who called Berg.Berg won half of that year’s prize for basic research into nucleic acids and for “certain aspects of recombinant DNA.” The other half was shared by Frederick Sanger and Walter (Wally) Gilbert for their discoveries about how to sequence DNA.advertisement Henry T. Greelycenter_img Our bipartisan bid to spur medical research still bearing fruit after 35 years Many scientists, at Stanford and elsewhere, made important contributions to the development of recombinant DNA; some have questioned why Berg was the sole recipient. The prizes are always difficult to award, particularly with the Nobel Committee’s self-imposed limit of no more than three awardees for any prize (except for the Peace Prize).Once the chemistry committee decided to recognize Sanger and Gilbert for sequencing — each had made substantial progress in very different ways — that left only one slot for recombinant DNA. No one doubts that Berg and his lab made major contributions to the field and were driving forces in its advance. But Berg had another role that made him stand out from the crowd. He was a leader, arguably the leader, in organizing a temporary moratorium on recombinant DNA research and in organizing and running the famous Asilomar conference on recombinant DNA at which the moratorium was discussed.advertisement Trending Now: Related: @HankGreelyLSJU When Indiana Democrat Senator Birch Bayh and Kansas Republican Senator Bob Dole first introduced into the 95th Congress the Small Business Nonprofit Organization Patent Procedures Act, it was a time of great concern about America’s economy, beset by the 1970s “stagflation” and the perceived economic challenge from Japan.Congress did not act on the bill that year, but Bayh and Dole re-introduced it in the 96th Congress. Although Democrats controlled both the Senate and the House, President Carter opposed the bill. He wanted a more government-directed path, like the approach taken in the Stevenson-Wydler Act. Russell Long (D-La.), the powerful chair of the Senate Finance Committee, opposed the bill from a more populist perspective. He wanted the government to get as much profit as possible from any patents. The bill did not pass either chamber before the November 1980 election.That election brought Ronald Reagan to the White House and also cost the Democrats 12 Senate seats, which would give the Republicans in the 97th Congress, starting in January 1981, their first Senate majority since 1954. One of the Democrats who would not be returning to the Senate was Birch Bayh, defeated by future Vice President Dan Quayle.The 96th Congress, still with a majority Democratic Senate, held a lame-duck session after the November election, one of 16 such sessions in the 39 Congresses since 1940. The urgency for it came from the lack of budget authority for most of the government, but also for some other important, difficult, and controversial legislation that had been put off until after the election.Strong support for Bayh-Dole in their ranks kept the soon-to-be majority Senate Republicans from opposing its passage. But for the bill to be voted on in that session required unanimous consent of the Senate — which meant a thumbs up from Long. He acquiesced, supposedly out of respect and friendship for his departing colleague, Birch Bayh.President Carter did not give any indication whether he would sign the bill. The Constitution gives a president 10 days (not counting Sundays) to veto a bill, sign a bill, or let it become law without his signature. On the last possible day, December 12, Carter signed it.It is ironic that the Cohen-Boyer patent was issued and assigned to Stanford and UCSF before Bayh-Dole made it easier for universities to patent inventions that had benefited from federal funding. Both institutions had used money from the NIH and private foundations in the relevant recombinant DNA research, but they did not have to wait for Bayh-Dole’s passage to patent the invention. A pre-existing patent agreement existed between the federal Department of Health, Education, and Welfare (the precursor of the Department of Health and Human Services) and Stanford’s Office of Technology Licensing that allowed Stanford and UCSF to patent the technology before Bayh-Dole took effect.So in two days short of two months, the nascent biotech industry and university biotechnology research were propelled into the future with a Nobel prize, a stunning biotech IPO, two research commercialization acts, and a fundamental patent. And no one at the time seemed to notice their collective importance. True, there were other things going on then. During the first three weeks, Republican Ronald Reagan, who at the time seemed to be at the conservative extreme of American politics, was challenging moderately conservative Democrat Jimmy Carter, and on November 4 defeated Carter after only one term in office. For the entire period, 53 U.S. diplomats and citizens from the American Embassy in Tehran, Iran, were being held captive, marking their first full year of detention in early November. The economy was still reeling from the second oil crisis and its resulting high inflation (and was about to plunge into a sharp recession).In the midst of all that, largely unnoticed, the building blocks of a new era in biotechnology came together.And so it often is with history. Some crucial events are obvious; others sneak up on us. And blatant or obscure, through all these momentous historical periods, we go on with our day-to-day jobs, loves, and lives, only rarely looking back and noticing the times in which we lived — sometimes only after 40 years.Henry T. Greely, J.D., is professor of law and professor by courtesy of genetics at Stanford University, where he directs the Stanford Center for Law and the Biosciences and chairs the steering committee for the Stanford Center for Biomedical Ethics. He thanks Jacob Sherkow and Robert Cook-Deegan for their helpful comments on the article, as well as his research assistants, Brittany Cazakoff and Cassidy Amber Pomeroy-Carter. The announcement that Stanford’s Paul Berg won the 1980 Nobel Prize for Chemistry started an amazing two-month period that shaped the future of biotech. Hulton Archive/Getty Images Comparing the Covid-19 vaccines developed by Pfizer, Moderna, and Johnson & Johnson First OpinionThe two months in 1980 that shaped the future of biotech last_img read more

2018 Remembered: New UK supermarket is coming to Laois and will create more than 20 jobs

first_img Facebook WhatsApp GAA Twitter 2018 Remembered: New UK supermarket is coming to Laois and will create more than 20 jobs Pinterest GAA Pinterest WhatsApp TAGSIceland Here are all of Wednesday’s Laois GAA results Facebookcenter_img Twitter Home News Business 2018 Remembered: New UK supermarket is coming to Laois and will create… NewsBusiness They are advertising for an Assistant Manager in a new store in Portlaoise, stating that they will be leading, “a team of over 20 colleagues.”“Due to our continued expansion an opportunity has come up to join our team as an Assistant Manager in our new Portlaoise Store.“Working alongside the Store Manager you will lead a team of over 20 colleagues in this store. So if you have Retail Management experience preferably in Grocery Retail and thrive in a fast-paced, high turnover environment then this could be the move you are waiting for,” the company states.It does not state where the new supermarket will be located in Portlaoise.This is good news for all those looking to stay healthy over January as Iceland have their own Slimming World Range.SEE ALSO – Four schools in Laois set to undergo major improvement works next summer RELATED ARTICLESMORE FROM AUTHOR In January the news was announced that frozen food supermarket chain Iceland was coming to Portlaoise.Iceland opened in Gandon Court, Mountmellick Road, Portlaoise on August. This marked the third Iceland store opening this year for the retailer.The new store opening brought an initial 37 new jobs to Portlaoise. It is the currently the biggest Iceland store in the country spanning 19,000sq. ft.Iceland, the frozen food supermarket chain, is coming to Portlaoise and creating at least 22 jobs.The UK based supermarket already has 19 stores around the republic of Ireland.The store is expected to arrive in the first few months of 2018.Advertising for Assistant Manager Previous articleIn Pictures: Abbeyleix packed with action for the annual St Stephen’s Day HuntNext articleIn Pictures: Ballyroan kicks off the cobwebs with its annual St Stephen’s Day run LaoisToday Reporter By LaoisToday Reporter – 28th December 2018 Kelly and Farrell lead the way as St Joseph’s claim 2020 U-15 glory GAA 2020 U-15 ‘B’ glory for Ballyroan-Abbey following six point win over Killeshinlast_img read more

Toyota C-HR available in Des Hughes Motors

first_imgHome Motors Toyota C-HR available in Des Hughes Motors MotorsSponsored Previous articleGrant of almost €400,000 on the way to four Laois townsNext articleLaois swimmer nominated for Young Athlete of the Year and she needs your votes LaoisToday Reporter Twitter Pinterest The Toyota C-HR arrived on the market three years ago as Toyota’s first compact crossover model and is available to purchase in Des Hughes Motors in Portlaoise.Its combination of striking design, athletic handling and efficient powertrains has so far attracted some 8,000 sales in Ireland, 90% of which have been specified with the self-charging hybrid powertrain.Toyota is now building on that strong customer appeal and sales momentum with the arrival of the 2020 Toyota C-HR.Developed by our European research and development division, its refinements include improvements in dynamic performance, subtle changes to the exterior and interior designs, and the introduction of the latest Toyota multimedia technology, which includes Apple CarPlay and Android Auto smartphone integration.The 2020 Toyota C-HR also allows customers to choose between two different hybrid powertrains, which is a unique opportunity within the C-SUV segment.The established 120bhp 1.8-litre hybrid powertrain remains, albeit upgraded with a new lithium-ion high-voltage battery pack, but it is now joined by a new 2.0-litre hybrid system that produces 182bhp.As well as greater power and high efficiency, these 2.0-litre versions benefit from uprated suspension and improved noise and vibration countermeasures.The coupe-like lines of the new C-HR remain as distinctive as ever.However, subtle changes have been applied to simplify and refine the exterior aesthetic, while the headlights and rear light clusters have been reconfigured to illuminate with the latest LED technology.2020 Toyota C-HR: Irish model range and pricesThe 2020 Toyota C-HR is on sale now with customer deliveries from January 2020. The range follows the familiar Irish grade structure: entry level Luna, mid-range Sport, sporty Luna Sport and top-of-the-range Sol models.LunaPowertrain: 1.8 litre HybridPrice: €31,700Key Equipment: 17-inch alloy wheels, reversing camera, dual-zone automatic air conditioning, multimedia system with touchscreen, Apple CarPlay and Android Auto smartphone integration, Toyota Safety Sense, LED reflector headlights.SportPowertrain: 1.8 litre HybridPrice: €32,950Key Equipment: 18-inch alloy wheels, rear privacy glass, piano black console, rain-sensing windscreen wipers, Intelligent Clearance Sonar with auto brake and parking sensors, auto-dimming rear-view mirror, heated front seats with power lumbar adjustment.Luna SportPowertrain: 1.8 Litre Hybrid/2.0 Litre HybridPrice: €34,550/€38,350Key Equipment: 18-inch alloy wheels, Bi-Tone paint scheme. rear LED lights, adaptive LED headlights, LED fog lights, puddle lights driver’s seat Spot Monitor, Smart EntrySolPowertrain: 1.8 Litre Hybrid/2.0 Litre HybridPrice: €36,050/€38,200Key Equipment: 18-inch Dynamic alloy wheels,1/2 leather luxury brown upholstery Rear Cross Traffic Alert with auto braking, Blind Spot Monitor, adaptive LED lights front and rear LED fog lights, Satellite Navigation, Self-Parking, puddle lights, 2020 Toyota C-HR: January OffersScrappage Booster up to €3,000Or a Low APR from 3.9%*3 Years Servicing as StandardPlus the Hybrid AdvantagePrices on the road, Inc. Delivery ChargesIf you would like more information, a personalised Trade-In valuation or competitive finance quote you can call into Des Hughes Motors, on the Dublin Road in Portlaoise or call any member of the sales team on 057 86 21742.SEE ALSO – Check out the Des Hughes website here  By LaoisToday Reporter – 9th January 2020 News Facebook Twitter Toyota C-HR available in Des Hughes Motors WhatsApp RELATED ARTICLESMORE FROM AUTHOR TAGSDes Hughes MotorsToyota GAA Pinterest Facebook WhatsApp GAA Kelly and Farrell lead the way as St Joseph’s claim 2020 U-15 glory 2020 U-15 ‘B’ glory for Ballyroan-Abbey following six point win over Killeshin Bizarre situation as Ben Brennan breaks up Fianna Fáil-Fine Gael arrangement to take Graiguecullen-Portarlington vice-chair rolelast_img read more

Fundata awards Western Canada mutual funds

“Award winners have demonstrated consistent, outstanding risk-adjusted performance through the year measured against their peers right across the country,” said Janny Vincent, [resident and CEO of Fundata, in a release. Vincent pointed out that this is a significant achievement, considering the Canadian fund universe consists of some 23,000 funds entries, and less than 2% of the investment fund products available in Canada have received a FundGrade A+ rating. The following funds, based in Western Canada, all received the Fundata FundGrade A+ Rating: Compass Balanced Growth Portfolio Compass Balanced Portfolio Compass Conservative Portfolio Compass Conservative Balanced Portfolio DFA Investment Grade Fixed Income Fund Mawer Balanced Fund Mawer Tax Effective Balanced Fund Mawer New Canada Fund Mawer Canadian Equity Fund Mawer Global Equity Fund Mawer Global Small Cap Fund Mawer International Equity Fund Pender Small Cap Opportunities Fund Phillips, Hager & North Canadian Equity Value Fund Steadyhand Equity Fund Steadyhand Small-Cap Equity Fund “We feel that identifying and honouring Western Canada’s top-notch investment funds with the FundGrade A+ Rating signifies a very unique accomplishment by the fund companies and will allow investors and advisors to easily identify the best of the best over the past year,” added Vincent. The FundGrade A+ Rating is the first and only totally objective, transparent, score-based calculation using a grade-point average that ranks funds to determine the annual “best-of-the-best” ratings. As such, the FundGrade A+ Rating provides investors, advisors, and fund managers with a single, reliable, easy-to-understand fund-performance rating based an entire calendar year. For more information and a complete list of the funds receiving the Fundata FundGrade A+ Rating for the calendar year 2012, please visit the Fundata FundGrade A+ website. Franklin Templeton launches new real asset fund Facebook LinkedIn Twitter Keywords Awards,  Mutual fundsCompanies Fundata Canada Inc. Share this article and your comments with peers on social media IG Wealth amends product shelf Related news Purpose looks to fill retirement income gap with longevity fund Fundata Canada Inc. honoured Western Canada-based mutual fund winners of the Fundata FundGrade A+ Ratings for 2012 at a special presentation in Vancouver on Monday. The presentation was a follow-up to a similar event in Toronto last week, and was designed specifically to highlight the achievements of mutual funds based in Western Canada. IE Staff read more

Supervised Community Accommodation service to end

first_imgSupervised Community Accommodation service to end Minister for Children and Youth Justice and Minister for Multicultural Affairs The Honourable Leanne LinardQueensland’s Supervised Community Accommodation service (SCA) will conclude at the end of January following the completion of a final independent review.Minister for Children and Youth Justice Leanne Linard said SCAs were introduced in 2017 as an accommodation option for young people on bail in the Youth Justice system.“Ernst and Young’s final independent evaluation found SCAs are doing their job of providing appropriate services and reducing offences by residents, but are underutilised and alternative options are more cost effective,” she said.“After considering the report, we’ve decided to close the SCAs because we are committed to acting on the evidence.”There are two SCA houses in Townsville and one each at Carbrook and Logan in South East Queensland.“We will be working with SCA teams, young people staying at a SCA and other agencies to transition to alternative accommodation and, most importantly, provide support,” Ms Linard said.“Since the SCAs came online, the government has launched or expanded other programs, including co-responder, Transition to Success, Project Lighthouse and StreetCred.“Coupled with intensive case management, they are having a significant impact.“The Palaszczuk Government’s investment of more than half-a-billion dollars in new detention beds and early intervention programs to reduce youth crime is getting results with a significant drop in the number of young offenders in Queensland.”In the 12 months to June this year, there has been a 23 per cent fall in the number of 10 to 17-year-olds with a charged offence in Queensland.Ms Linard said community safety continued to be paramount and where young people were an unacceptable risk to that safety or had been found guilty of serious offences, the courts could place them in detention.“The Palaszczuk Government has invested more than $550 million in evidence-based programs and youth detention centre beds to reduce youth crime and stop reoffending,” she said.The Ernst and Young report can be found here. /Public Release. This material comes from the originating organization and may be of a point-in-time nature, edited for clarity, style and length. View in full here. Why?Well, unlike many news organisations, we have no sponsors, no corporate or ideological interests. We don’t put up a paywall – we believe in free access to information of public interest. Media ownership in Australia is one of the most concentrated in the world (Learn more). Since the trend of consolidation is and has historically been upward, fewer and fewer individuals or organizations control increasing shares of the mass media in our country. According to independent assessment, about 98% of the media sector is held by three conglomerates. This tendency is not only totally unacceptable, but also to a degree frightening). Learn more hereWe endeavour to provide the community with real-time access to true unfiltered news firsthand from primary sources. It is a bumpy road with all sorties of difficulties. We can only achieve this goal together. Our website is open to any citizen journalists and organizations who want to contribute, publish high-quality insights or send media releases to improve public access to impartial information. You and we have the right to know, learn, read, hear what and how we deem appropriate.Your support is greatly appreciated. All donations are kept completely private and confidential.Thank you in advance!Tags:Australia, children, community, crime, detention, Government, Impact, Investment, justice, Logan, Minister, Palaszczuk, project, QLD, Queensland, Safety, Townsville, younglast_img read more

Qld company’s 15-min rapid Covid-19 test takes fight to Europe

first_imgQld company’s 15-min rapid Covid-19 test takes fight to Europe JOINT STATEMENTQueensland company AnteoTech has won a vital European accreditation for its 15-minute COVID-19 rapid test.AnteoTech now has Conformitè Europëenne Mark registration for its innovative point-of-care COVID-19 antigen rapid test platform, EuGeni.This meets crucial health and safety conditions in Europe and the United Kingdom.Premier Annastacia Palaszczuk said the Queensland Government was proud to provide support to companies developing technology to fight COVID-19.“Queensland is on the forefront of fighting the COVID pandemic globally, creating more jobs and economic opportunities locally,” she said.“Earlier this year we committed $1.4 million to help AnteoTech to progress the COVID-19 rapid test from prototype through to product launch.“Now AnteoTech is taking the pandemic fight to Europe.“This is world leading technology being produced in Queensland and exported overseas.“We’ll continue to support our best and brightest to develop technology that can create jobs here in Queensland and help fight the global pandemic.”Treasurer and Minister for Investment Cameron Dick said Queensland ingenuity was proving crucial in stopping the spread of COVID-19.“The COVID health solutions being produced here in Queensland are world-leading and life-saving,” Mr Dick said.“We’ve already seen Queensland start-up Ellume secure a $304 million US government contract for their COVID-19 self-testing kit,” she said.“This tick from Europe will help AnteoTech accelerate commercialisation of their product in Australia, generating more than $2 million in private sector investment and creating five new jobs while strengthening vital industry supply chains.”The COVID-19 rapid test is based on AnteoTech’s proprietary binding technology coupled with global advancements in assay detection systems which provides valuable decision-making support for the early detection and isolation of infected patients.Member for Toohey Peter Russo said on product launch in Australia AnteoTech will have capacity to produce a large quantity of tests per week at its facility at Eight Mile Plains.“They will partner with contract manufacturers to scale-up test kit production to meet increased demand to satisfy the Australian market,” he said.“AnteoTech’s next step is to gain approval from the Therapeutic Goods Administration to start manufacturing here and get Australians using this rapid-screening technology.”AnteoTech CEO Derek Thomson said the launch of the EuGeni Platform provides a strong foundation for AnteoTech to grow a suite of qualitative and quantitative tests for the Point-of-Care market.“I am excited by the immediate opportunity and the leverage opportunities that lie ahead of us,” he said.“CE Mark registration for the COVID-19 antigen rapid test platform provides AnteoTech with an opportunity to capture some of the large and growing European antigen rapid test market.“With the support of the Queensland Government, we hope not only to successfully deliver this project, but create valuable supply chains to ensure the success of future projects.“I would also like to thank the Queensland Government for their contribution through the Essential Goods and Supply Chain Program, to the commercialisation of our test and platform.”The Essential Goods and Supply Chain Program plays an important role in Queensland’s economic recovery strategy /Public Release. This material comes from the originating organization and may be of a point-in-time nature, edited for clarity, style and length. View in full here. Why?Well, unlike many news organisations, we have no sponsors, no corporate or ideological interests. We don’t put up a paywall – we believe in free access to information of public interest. Media ownership in Australia is one of the most concentrated in the world (Learn more). Since the trend of consolidation is and has historically been upward, fewer and fewer individuals or organizations control increasing shares of the mass media in our country. According to independent assessment, about 98% of the media sector is held by three conglomerates. This tendency is not only totally unacceptable, but also to a degree frightening). Learn more hereWe endeavour to provide the community with real-time access to true unfiltered news firsthand from primary sources. It is a bumpy road with all sorties of difficulties. We can only achieve this goal together. Our website is open to any citizen journalists and organizations who want to contribute, publish high-quality insights or send media releases to improve public access to impartial information. You and we have the right to know, learn, read, hear what and how we deem appropriate.Your support is greatly appreciated. All donations are kept completely private and confidential.Thank you in advance!Tags:Australia, Australian, detection, early detection, Europe, european, Government, health and safety, Investment, Palaszczuk, production, QLD, Queensland, supply chain, technology, Therapeutic Goods Administration, United Kingdomlast_img read more